ALXN2050 for Kidney Disease
Trial Summary
What is the purpose of this trial?
This trial tests a new medication, ALXN2050, in adults with serious kidney diseases (LN or IgAN). The goal is to improve kidney function and manage symptoms.
Eligibility Criteria
Adults aged 18-75 with Lupus Nephritis (LN) or IgA Nephropathy (IgAN), who meet specific diagnostic criteria, including certain levels of proteinuria and active disease requiring treatment. Participants must have stable blood pressure and kidney function, and not be planning a transplant or have other significant health issues.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Evaluation
Participants receive blinded treatment with ALXN2050 or placebo for initial evaluation
Extended Treatment
Participants continue blinded treatment with ALXN2050 or placebo
Open-label Extension
Participants may opt into continuation of treatment with ALXN2050 long-term
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ALXN2050
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alexion Pharmaceuticals, Inc.
Lead Sponsor
Dr. Alberto R. Martinez
Alexion Pharmaceuticals, Inc.
Chief Medical Officer since 2010
MD from University of Sao Paulo
Marc Dunoyer
Alexion Pharmaceuticals, Inc.
Chief Executive Officer since 2021
PhD in Molecular Biology
Alexion
Lead Sponsor
Marc Dunoyer
Alexion
Chief Executive Officer since 2021
PhD in Molecular Biology, University of Brussels
Christophe Hotermans
Alexion
Chief Medical Officer since 2021
MD, University of Leuven
Alexion Pharmaceuticals
Lead Sponsor
Marc Dunoyer
Alexion Pharmaceuticals
Chief Executive Officer since 2021
B.A. in Psychology from the University of New Hampshire
Christophe Hotermans
Alexion Pharmaceuticals
Chief Medical Officer since 2023
MD